However, univariate analysis of present study revealed that CD34 positive GIST patients had better outcome than CD34 negative patients (5-yaer OS, 87.2% vs. 75.4%, P = 0.006; 5-year RFS, 80.6% vs. 64.3%, P = 0.001). Here, CD34 is linked to gastrointestinal stromal tumor.